1996;335(16):1169–1175 156 Babcock M, de Silva D, Oaks R, et al Regulation of mitochondrial iron accumulation by yfh1p, a putative homolog of frataxin Science 1997;276(5319):1709–1712 157 Puccio H, Simon D, Cossee M, et al Mouse models for friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits Nat Genet 2001;27(2):181–186 158 Perdomini M, Belbellaa B, Monassier L, et al Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia Nat Med 2014;20(5):542–547 159 Rotig A, de Lonlay P, Chretien D, et al Aconitase and mitochondrial iron-sulphur protein deficiency in friedreich ataxia Nat Genet 1997;17(2):215–217 160 Regner SR, Lagedrost SJ, Plappert T, et al Analysis of echocardiograms in a large heterogeneous cohort of patients with friedreich ataxia Am J Cardiol 2012;109(3):401–405 161 Kipps A, Alexander M, Colan SD, et al The longitudinal course of cardiomyopathy in Friedreich's ataxia during childhood Pediatr Cardiol 2009;30(3):306–310 162 Raman SV, Phatak K, Hoyle JC, et al Impaired myocardial perfusion reserve and fibrosis in friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome Eur Heart J 2011;32(5):561–567 163 Weidemann F, Rummey C, Bijnens B, et al The heart in friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms Circulation 2012;125(13):1626–1634 164 Pousset F, Legrand L, Monin ML, et al A 22year Follow-up study of Long-term cardiac outcome and predictors of survival in friedreich ataxia JAMA Neurol 2015;72(11):1334–1341 165 Mottram PM, Delatycki MB, Donelan L, et al Early changes in left ventricular long-axis function in friedreich ataxia: relation with the FXN gene mutation and cardiac structural change J Am Soc Echocardiogr 2011;24(7):782–789 166 Reetz K, Dogan I, Costa AS, et al Biological and clinical characteristics of the European Friedreich's ataxia consortium for translational studies (EFACTS) cohort: a cross-sectional analysis of baseline data Lancet Neurol 2015;14(2):174–182 167 Corben LA, Lynch D, Pandolfo M, et al Consensus clinical management guidelines for friedreich ataxia Orphanet J Rare Dis 2014;9:184 168 Kearney M, Orrell RW, Fahey M, Brassington R, Pandolfo M Pharmacological treatments for friedreich ataxia Cochrane Database Syst Rev 2016;(8) [CD007791] 169 Mariotti C, Solari A, Torta D, et al Idebenone treatment in friedreich patients: one-year-long randomized placebo-controlled trial Neurology 2003;60(10):1676–1679 170 Lagedrost SJ, Sutton MS, Cohen MS, et al Idebenone in friedreich ataxia cardiomyopathyresults from a 6-month phase III study (IONIA) Am Heart J 2011;161(3):639–645.e1 171 Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH Coenzyme q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme q10 therapy Eur J Neurol 2008;15(12):1371–1379 172 Elincx-Benizri S, Glik A, Merkel D, et al Clinical experience with deferiprone treatment for friedreich ataxia J Child Neurol 2016;31(8):1036–1040 173 Colucci WS, Lorell BH, Schoen FJ, Warhol MJ, Grossman W Hypertrophic obstructive